Perrigo closes Qualis deal
This article was originally published in The Tan Sheet
Executive Summary
Perrigo completes its acquisition of Des Moines, Iowa-based store-brand pediculicide manufacturer Qualis for $12 mil. cash, the firm announces July 11. The deal, initially announced in March, gives the private labeler five OTC products equivalent to Bayer's Rid and Insight Pharmaceuticals' Nix lice products, which are expected to add more than $10 mil. to annual sales, the Allegan, Mich.-based firm says (1"The Tan Sheet" March 12, 2007, In Brief)...
You may also be interested in...
Perrigo enters lice market
The Allegan, Mich.-based private labeler enters an agreement March 7 to expand its offerings into a new category by paying $12 mil. in cash for Qualis's store-brand pediculicide products in a transaction the firms expect to close around June 30. In a release, Perrigo President and CEO Joe Papa says the acquisition will bring "a range of products that fits nicely within our Consumer Healthcare business portfolio." The firm says adding Des Moines, Iowa-based Qualis's OTC product formulations similar to the Rid and Nix brands should increase its sales by $10 mil. annually...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.